

10/571836

14P12 Rec'd PCT/US

10/2006

S/N Unknown

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: SUN Serial No.: Unknown

Filed: Concurrent herewith Docket No.: 09548.1019USWO


Title: A SUPERANTIGEN FUSION PROTEIN FOR ANTI-CANCER THERAPY
AND METHODS FOR THE PRODUCTION OF (AS AMENDED)

CERTIFICATE UNDER 37 CFR 1.10

Express Mail mailing label number: EV 775295299 US

Date of Deposit: March 15, 2006

I hereby certify that the papers listed below are being deposited with the United States Postal Service Express Mail Post Office to Addressee service under 37 CFR 1.10 in an envelope addressed to: Mail Stop Application, Commissioner for Patents, P.O. Box 1450, Arlington, VA 22313-1450.

By: 

Name: Abbie Larkin

INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(c))

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Commissioner:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted within three months of the filing date of the above-identified application, which is not an application under 37 C.F.R. § 1.53(d). Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. § 1.98(a)(2), a copy of each non-U.S. document or other information listed on the enclosed Form 1449 is provided. Applicants believe the references from the International Search Report are available to the Examiner, and therefore only abstracts of some of the documents are provided herewith, as indicated on the Form 1449.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or

10/571
AP12 Rec'd PCT/E. 15 MAR 2006

otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.


Please charge any additional fees or credit any overpayment to Deposit Account No. 50-3478.

Respectfully submitted,

HAMRE, SCHUMANN, MUELLER &
LARSON, P.C.
P.O. Box 2902-0902
Minneapolis, MN 55402-0902
(612) 455-3800

Dated: March 15, 2006

By: 
Michael D. Schumann
Reg. No. 30,422
MDS/BAW/acp



Date Mailed: March 15, 2006

Sheet 1 of 1

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)		Docket Number: 09548.1019USWO	Application Number: Unknown 10/571836
		Applicant: SUN	
		Filing Date: Concurrent herewith	Group Art Unit Unknown

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES
	WO 03/002143	01/2003	WIPO			Abstract only
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
		Veenendaal et al., "In vitro and in vivo studies of a VEGF121/rGelonin chimerric fusion toxin targeting the neovasculature of solid tumors." Proc Natl Acad Sci USA. Vol. 99, No. 12, June 11, 2002, pp. 7866-7871. (abstract only)				
		Yang Lianjun et al., "Preparation of the Conjugate of Monoclonal Antibody and Staphylococcal Enterotoxin A and Its Anti-hepatoma Effect", JOURNAL OF BEIHUA UNIVERSITY (Natural Science), Vol. 2, No. 3, June 2001, pp. 209-212.				
		Husain et al., "Complete regression of established human glioblastoma tumor xenograft by interleukin-4 toxin therapy." Cancer Research, August 15, 1998, Vol. 58, No. 16, pp. 3649-3653. (abstract only)				
		Dore et al., "Expression and activity of a recombinant chimeric protein composed of pokeweed antiviral protein and of human interleukin-2", FEBS Letters, January 27, 1997, Vol. 402, No. 1, pp. 50-52. (abstract only)				
		Schmidt et al., "Cytotoxic Activity of Recombinant bFGF-rViscumin Fusion Proteins", Biochemical and Biophysical Research Communications, 2000, Vol. 277, pp. 499-506.				
		Kihara A. Pastan I., "Small Chimeric toxins containing only transforming growth factor alpha and domain III of Pseudomonas exotoxin with good antitumor activity in mice." Cancer Research, October 1, 1994, Vol. 54, No. 19, pp. 5154-5159. (abstract only)				

52835

PATENT TRADEMARK OFFICE

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	